Business Context and Reporting Period
Company: Neuralstem, Inc. (Note: Request metadata listed "Palisade Bio," but the filing text identifies the registrant as Neuralstem, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Neuralstem is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases using human neural stem cells and small molecule compounds. The company has no commercial products and generates no revenue. Its primary development focus is a Phase I clinical trial for Amyotrophic Lateral Sclerosis (ALS), for which the FDA approved an Investigational New Drug (IND) application in September 2009. The first patient was dosed on January 21, 2010.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,364,363) | $(11,830,798) |
| Total Operating Expenses | $10,466,549 | $11,831,973 |
| Research & Development Expenses | $5,346,904 | $6,513,349 |
| General & Administrative Expenses | $5,030,981 | $5,252,863 |
| Cash and Cash Equivalents (Year End) | $2,309,774 | $4,903,279 |
| Net Cash Used in Operating Activities | $(5,144,820) | $(6,860,039) |
| Stockholders' Equity (Deficit) | $(5,015,456) | $4,203,245 |
| Accumulated Deficit | $(67,566,831) | $(57,486,795) |
Liquidity: As of December 31, 2009, the company had a monthly cash burn rate of approximately $600,000. Management estimated cash on hand would fund operations for at least 12 months from the balance sheet date.
Material Changes vs. Prior Period
- Accounting Reclassification: Effective January 1, 2009, the company adopted new FASB guidance (EITF 07-05) requiring the reclassification of 8,547,762 warrants from equity to liability status due to anti-dilution and price reset features. This resulted in a $6.8 million long-term warrant liability and a reduction of stockholders' equity by approximately $2.8 million, contributing to the shift from positive equity in 2008 to a deficit in 2009.
- Expense Reduction: Total operating expenses decreased by 12% ($1.37 million) compared to 2008. R&D expenses dropped 18% due to the completion of FDA application costs in 2008 and reduced non-cash stock-based compensation. G&A expenses decreased 4%.
- Cash Position: Cash and cash equivalents decreased by 53% ($2.59 million) from 2008 to 2009, primarily due to operating losses and the postponement of new financing activities until the first quarter of 2010.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Subsequent Events:
- Financing: In Q1 2010, the company secured approximately $7.3 million in net proceeds from the exercise of Series A, B, C, and D warrants. As of March 16, 2010, cash on hand was approximately $7.5 million, providing funding through Q1 2011.
- Clinical Progress: The first ALS patient was treated on January 21, 2010. The company plans to file an IND for a small molecule compound for depression in late 2010 or early 2011.
Risks and Contingencies:
- Listing Compliance: The company was notified by NYSE Amex in 2009 that it did not meet stockholders' equity requirements due to the warrant reclassification. While the exchange allowed continued listing subject to a compliance plan, the company remains under monitoring. Failure to regain compliance could result in delisting.
- Litigation: Ongoing patent litigation with StemCells, Inc. regarding stem cell culture compositions. The outcome is uncertain and could result in significant costs or restrictions on technology use.
- Capital Needs: The company has no revenue and relies entirely on external financing. Failure to raise additional capital could force the delay or elimination of research programs.
- Key Personnel: The company is dependent on two key executives (CEO Richard Garr and CSO Karl Johe). Their employment agreements contain significant anti-termination provisions that could cost the company up to $1 million per contract plus accelerated option vesting upon termination.
Investor Verification Checklist
- Warrant Liability Impact: Verify the current fair value of the warrant liabilities and the impact of stock price volatility on future earnings, as these are marked-to-market quarterly.
- Cash Runway: Confirm the current cash balance and burn rate to validate the sufficiency of the $7.3 million raised in Q1 2010 to fund the ALS trial and operations through 2011.
- Listing Status: Check current SEC filings or exchange notices to confirm the company's compliance status with NYSE Amex listing requirements regarding stockholders' equity.
- Clinical Trial Data: Monitor upcoming reports for safety and efficacy data from the Phase I ALS trial, as the company's viability depends on this single product candidate.
- Legal Proceedings: Review updates on the patent litigation with StemCells, Inc., as an adverse ruling could threaten the company's core technology platform.